Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus

被引:16
作者
Wani, S
Sampliner, RE
Weston, AP
Mathur, S
Hall, M
Higbee, A
Sharma, P
机构
[1] Dept Vet Affairs Med Ctr, Kansas City, MO 64128 USA
[2] Univ Kansas, Sch Med, Kansas City, MO USA
[3] So Arizona Vet Affairs Hlth Care Syst, Tucson, AZ USA
[4] Arizona Hlth Sci Ctr, Tucson, AZ 85724 USA
关键词
D O I
10.1111/j.1365-2036.2005.02626.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Barrett's oesophagus patients may continue to have abnormal oesophageal acid exposure on proton pump inhibitor therapy. The effect of factors such as Barrett's oesophagus length, hiatal hernia size and Helicobacter pylori infection on intra-oesophageal pH in Barrett's oesophagus patients has not been adequately studied. Aim: To evaluate oesophageal acid exposure in a large Barrett's oesophagus population on b.d. proton pump inhibitor therapy and determine clinical factors predicting normalization of intra-oesophageal pH on therapy. Methods: Barrett's oesophagus patients were studied using 24 h pH monitoring to evaluate intra-oesophageal acid suppression on b.d. dosing of rabeprazole. Results: Forty-six Barrett's oesophagus patients completed the study. Median total percentage time pH < 4 was 1.05% (range: 0-29.9%) in the entire group and respective values for upright and supine percentage time pH < 4 were 1.15% and 0%. However, 34 of the Barrett's oesophagus patients (73.9%) had a normal pH study (median total percentage time pH < 4: 0.2%) and 12 patients (26.1%) had an abnormal result (median total percentage time pH < 4: 9.3%). There were no significant differences between patients with a normal and abnormal 24 h pH result with respect to age, Barrett's oesophagus length, hiatal hernia size and presence of H. pylori infection. Conclusions: Approximately 25% of Barrett's oesophagus patients continue to have abnormal total intra-oesophageal pH profiles despite b.d. proton pump inhibitor therapy. Factors such as age, Barrett's oesophagus length and hiatal hernia size cannot be used to predict persistent abnormal intra-oesophageal pH on proton pump inhibitor.
引用
收藏
页码:627 / 633
页数:7
相关论文
共 33 条
[1]   Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy [J].
Basu, KK ;
Bale, R ;
West, KP ;
de Caestecker, JS .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (11) :1187-1192
[2]   CONCENTRATION OF REFLUXED ACID AND ESOPHAGEAL MUCOSAL INJURY [J].
BREMNER, RM ;
CROOKES, PF ;
DEMEESTER, TR ;
PETERS, JH ;
STEIN, HJ .
AMERICAN JOURNAL OF SURGERY, 1992, 164 (05) :522-527
[3]   Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation [J].
Carlson, N ;
Lechago, J ;
Richter, J ;
Sampliner, RE ;
Peterson, L ;
Santella, RM ;
Goldblum, JR ;
Falk, GW ;
Ertan, A ;
Younes, M .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (06) :1340-1345
[4]   Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus [J].
Cooper, BT ;
Neumann, CS ;
Cox, MA ;
Iqbal, TH .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1998, 12 (09) :893-897
[5]   Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus [J].
不详 .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10) :1865-1865
[6]   Correlation of oesophageal acid exposure with Barrett's oesophagus length [J].
Fass, R ;
Hell, RW ;
Garewal, HS ;
Martinez, P ;
Pulliam, G ;
Wendel, C ;
Sampliner, RE .
GUT, 2001, 48 (03) :310-313
[7]  
Fass R, 2000, ALIMENT PHARM THER, V14, P597
[8]   Dynamic effects of acid on Barrett's esophagus - An ex vivo proliferation and differentiation model [J].
Fitzgerald, RC ;
Omary, MB ;
Triadafilopoulos, G .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (09) :2120-2128
[9]   Recent developments in the molecular characterization of Barrett's esophagus [J].
Fitzgerald, RC ;
Triadafilopoulos, G .
DIGESTIVE DISEASES, 1998, 16 (02) :63-80
[10]  
Fouad YM, 1999, ALIMENT PHARM THERAP, V13, P1467